Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SBT777101
- Development stage
- Phase 1
- Lead developer
- Sonoma Biotherapeutics
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
SBT777101 is an investigational autologous cell therapy composed of chimeric antigen receptor regulatory T cells (CAR-Tregs). The therapy is developed by collecting a patient's own immune cells (regulatory T cells), genetically modifying them to express a specific protein that targets markers associated with inflammation, and then re-infusing these engineered cells back into the patient. The goal is to dampen inflammation and restore immune balance in autoimmune and inflammatory diseases. SBT777101 is currently being evaluated in Phase 1 clinical trials for rheumatoid arthritis and hidradenitis suppurativa. It represents a next-generation approach using genome editing and target-specific cell therapy to modulate the immune response[1][2][3][6][8][9][10].
- Other names
- chimeric antigen receptor regulatory T cells targeting citrullinated proteinsCAR-Treg targeting citrullinated proteinsSBT-777101SBT777101SBT 777101
Beyond the preview
Go deeper on SBT777101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SBT777101.